

# Flip the coin: IL-7 and IL-7R in health and disease

João T. Barata<sup>1\*</sup>, Scott K. Durum<sup>2</sup> and Benedict Seddon<sup>3</sup>

**The cytokine IL-7 and its receptor, IL-7R, are critical for T cell and, in the mouse, B cell development, as well as differentiation and survival of naive T cells, and generation and maintenance of memory T cells. They are also required for innate lymphoid cell (ILC) development and maintenance, and consequently for generation of lymphoid structures and barrier defense. Here we discuss the central role of IL-7 and IL-7R in the lymphoid system and highlight the impact of their deregulation, placing a particular emphasis on their 'dark side' as promoters of cancer development. We also explore therapeutic implications and opportunities associated with either positive or negative modulation of the IL-7-IL-7R signaling axis.**

IL-7 is a 25 kDa secreted soluble globular protein encoded by the *IL7* gene. Its receptor (IL-7R) is a heterodimeric complex consisting of IL-7R $\alpha$  (encoded by *IL7R*) and the common  $\gamma$ -chain (encoded by *IL2RG*), shared with the receptors for IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. Although IL-7 was first characterized as a growth or survival factor for mouse T cell and B cell precursors, its central regulatory role throughout the lymphoid system has become increasingly evident. IL-7 is a critical developmental cue at every stage of T cell development, for both  $\alpha\beta$  and  $\gamma\delta$  lineages, and for development and survival of naive T cells as well as generation and maintenance of CD4 and CD8 memory. More recently, the discovery of the ILC family was accompanied by recognition that IL-7 was also essential for development and maintenance of many of its members, and consequently for the generation of lymphoid structures and barrier defense mechanisms mediated by these cells. Thus, IL-7 is tightly interwoven in the very fabric of the entire lymphoid system. It is perhaps unsurprising, then, that IL-7 and IL-7R are also implicated in the pathogenesis of different disease states mediated by dysregulation of lymphoid function. In this Review, we examine the physiology and pathophysiology of IL-7 and IL-7R, with particular emphasis on their involvement in the promotion of cancer, for which there is increasing evidence, and consider current opportunities and prospects to either exploit or target IL-7R-mediated signaling for therapeutic benefit.

## IL-7: expression of ligand and receptor

Insights into the functions of IL-7 are gained by examining where, and by which cells, the cytokine and its receptor are made. Although *Il7* mRNA was first detected at high levels in the thymus, more recent studies, and the generation of a number of *Il7* reporter systems, reveal that it is expressed in a broad range of tissues. Although there is incomplete agreement between different reporter strains about where *Il7* mRNA can be detected, this likely relates to the relative sensitivity of individual reporters coupled with variation in the extent to which IL-7 is actually produced (reviewed in ref. <sup>1</sup>). The highest levels of *Il7* mRNA expression appear to be in lymphoid organs such as thymus and lymph nodes (LNs). Perhaps it is surprising that they are considerably lower in spleen and bone marrow (BM). However, expression is also readily detectable in numerous non-lymphoid sites, such as intestine, lung, liver and skin (Fig. 1)<sup>1,2</sup>. In terms of specific cellular sources, early BM chimera experiments strongly suggested a non-hematopoietic source of IL-7; indeed, this proved to be the case, with cells of both epithelial and endothelial origin identified as sources. Thymic epithelial cells (TECs) and fibroblastic reticular cells (FRC) in LNs are important sources<sup>3,4</sup>,

whereas lymphatic endothelia in LNs<sup>5</sup>, afferent lymphatics<sup>6</sup> and bronchus-associated lymphoid tissue of the lung<sup>7</sup> may account for the high levels of IL-7 found in lymphatic fluid and ultimately blood serum. *Il7* is also constitutively expressed by keratinocytes in the skin, while expression is inducible in gut epithelia by IFN- $\gamma$  signaling. There are also reports of IL-7 expression in the brain, produced by neuronal progenitor cells<sup>8</sup>. Similarly, IL-7R $\alpha$  is broadly expressed throughout the lymphoid system: on B cell progenitors (but not mature B cells), ILCs, and throughout T cell development and maturation—although expression notably absent on selecting thymocytes and effector cells<sup>9,10</sup>. There are also emerging reports of IL-7R expression in the development of fetus-derived macrophages<sup>11</sup>, and outside of the hematopoietic system, lymphatic endothelial cells express IL-7R $\alpha$ <sup>6</sup> that is required to drive lymphatic expansion during formation of tertiary lymphoid structures<sup>12</sup>.

## Developmental functions and mechanisms of IL-7

As suggested by IL-7-deficient mice, IL-7 signaling is critical for development and maintenance of the entire lymphoid compartment, including T lymphocytes, B lymphocytes and ILCs. IL-7 is important throughout hematopoiesis, facilitating key lineage fate decisions (Fig. 2). Although some controversy over the identity of the earliest lymphoid progenitor cell remains, the so-called common-lymphoid progenitor (CLP) is in part characterized by its expression of IL-7R $\alpha$ <sup>13</sup>, and IL-7 signaling is thought to be important for lymphoid lineage specification, directing cells toward B rather than T lymphocyte fate<sup>14</sup>. Although mature B cells do not express the IL-7R, development of pre-pro-B cells from CLPs, and subsequent B cell development in the BM, absolutely requires IL-7 in the mouse (reviewed in ref. <sup>15</sup>), whereas in humans IL-7 appears to have a less critical role.

Lymphoid progenitors leave the BM and migrate to the thymus, giving rise to numerous lymphoid lineages whose development is dependent on, or influenced by, IL-7 signaling. Thymic NK cells, in contrast to conventional NK cells, depend on IL-7<sup>16</sup>. Pre-T cell progenitors lack expression of CD4 and CD8 surface antigens, and are termed double-negative (DN). In the mouse, DN cells are subdivided into four populations (DN1–DN4) on the basis of expression of CD44 and CD25. Development of  $\gamma\delta$  T cells from DN2 thymocytes is absolutely dependent on IL-7, and strong IL-7 signaling is thought to specifically favor  $\gamma\delta$  over  $\alpha\beta$  T cell lineage choice<sup>17</sup>. Developing  $\alpha\beta$  T cells also require IL-7 at DN3 and DN4 stages, whose function can be substituted only in part by Bcl2 overexpression<sup>18</sup> and PI3K activation<sup>19</sup>. IL-7 signaling appears to facilitate proliferation and differentiation of these DN stages by regulating

<sup>1</sup>Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. <sup>2</sup>Cancer and Inflammation Program, National Cancer Institute, Frederick, MD, USA. <sup>3</sup>Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, London, UK. \*e-mail: [joao\\_barata@medicina.ulisboa.pt](mailto:joao_barata@medicina.ulisboa.pt)


cell-growth genes such as those that encode CD98, and blocking expression of the transcriptional repressor, Bcl-6, in a Stat5-dependent process<sup>18</sup>. In contrast, positive selection of CD4 CD8 double-positive (DP) thymocytes does not require IL-7 signaling, and these cells lack functional IL-7R expression<sup>20</sup>. In mice, IL-7R functional inactivation is achieved by near-complete loss of IL-7R $\alpha$  surface expression coupled with high expression of SOCS proteins that inhibit cytokine signal transduction<sup>21</sup>. Cells that successfully pass selection re-express IL-7R in a multistep process dependent upon T cell antigen receptor (TCR) signaling<sup>9</sup>, and the transcription factors Foxo1<sup>22</sup>, Ets-1<sup>23</sup> and NF-kB<sup>24</sup>.

More recently, a family of lymphoid cells, ILCs, has been described that is important in inflammation, immune defense, tissue development and remodeling<sup>25</sup>. There are three broad classes of ILCs (groups 1, 2 and 3), whose regulation of effector function parallels that of conventional T cells, namely T<sub>H</sub>1-, T<sub>H</sub>2- and T<sub>H</sub>17-type. IL-7 is critical for development of both ILC2 and ILC3, and IL-7-deficient mice completely lack these subsets. Aside from T and B lymphopenia, it was later recognized that IL-7- and IL-7R-deficient mice also exhibited profound defects in secondary lymphoid structures, lacking normal sized LNs and Peyer's patches in the gut<sup>26</sup>. It is now recognized that development of these lymphoid structures requires a subset of Rorc-dependent ILC3: lymphoid tissue-inducer (LTi) cells. LTi cells are required to recruit LN organizer cells of stromal origin, together collaborating in the formation of mature lymphoid structures. In IL-7-deficient mice, these structures initially form normally but do not develop into LNs after birth. It appears that IL-7 signaling in LTi cells is required for the final stage of LN formation<sup>27,28</sup>. Indeed, IL-7-driven expansion of LTi cells is sufficient for ectopic development of lymphoid structures<sup>29</sup>.

### Control of immune homeostasis by IL-7

In contrast to B cells, T cells continue to express IL-7R in both naive and memory states, and IL-7 signaling is critical for long-term maintenance of all T cell populations. IL-7 promotes cell survival by modulating the intrinsic pathway of apoptosis<sup>30</sup>. The idea that competition for homeostatic resources limits the size of the T cell compartments is as attractive as it is enduring<sup>31</sup>, and there is evidence from mice lacking one or other CD4 or CD8 lineage that IL-7 constitutes one of the key cues controlling size of the T cell compartment.

Following activation, T cells rapidly lose expression of IL-7R $\alpha$ . Maintenance of IL-7R expression in peripheral T cells is dependent on the activity of Foxo1<sup>22</sup>. The activity of Foxo transcription factors is negatively regulated by Akt-mediated phosphorylation that is activated via PI3K by upstream TCR or IL-2 signaling<sup>32</sup>. This effectively uncouples effector cells from IL-7-dependent homeostatic control, relying rather on TCR and IL-2 signaling for survival and proliferation. Following a T cell immune response, most effector cells will undergo apoptosis, but some survive to become long-term memory cells. IL-7 signaling has a key role in the formation of this memory population. In the absence of antigen, TCR-dependent repression of IL-7R $\alpha$  expression is reversed, and effector T cells can re-express IL-7R $\alpha$ . In some settings at least, cells that re-express IL-7R $\alpha$  are the precursors of the long-term memory cells, suggesting that IL-7 could be instructing effectors to develop into memory cells<sup>33</sup>. However, there is also evidence that effector T cells are far more predisposed to undergo apoptosis than naive or memory T cells. Although re-expression of IL-7R can delay effector T cell death, the effector pool still undergoes a substantial contraction because the effector cells are less able to compete and survive in response to IL-7 than other T cells<sup>10</sup>. Nevertheless, IL-7 signaling represents a key gateway into the memory T cell pool, ensuring only the fittest effectors persist. Following establishment of memory, both CD4<sup>34</sup> and CD8 memory T cells<sup>35</sup> continue to be dependent on IL-7 for their long-term survival, although CD8 memory cells




**Fig. 1 | Atlas of IL-7 production.** IL-7 is produced in both primary (bone marrow and thymus) and secondary (lymph nodes and spleen) lymphoid organs, where it supports development and maintenance of lymphocyte populations. Production is also detected in nonlymphoid sites such as mucosal and epithelial layers, where it is important for maintaining intact barrier, as well as other sites such as the brain, where function is less clear.

also have a strong reliance on IL-15. Tissue-resident memory cells were recently recognized as important mediators of immunity in non-lymphoid organs, where they reside and are maintained. These populations do not recirculate and so their dependence on IL-7 for survival<sup>36</sup> likely explains why epithelial barriers have local sources of IL-7 production. Indeed, dendritic epidermal  $\gamma\delta$  T cells in the skin are also dependent in part on IL-7 for their survival<sup>37</sup>.

There is a growing body of evidence that ILC survival is IL-7-dependent<sup>38,39</sup> and that this accounts for some features of immune homeostasis that rely on IL-7. ILCs appear to be particularly sensitive to IL-7 levels. Competition for IL-7 with T cells appears to greatly restrict the size of the ILC compartment<sup>39</sup>, and it is notable that blockade of IL-7 in vivo affects ILCs more rapidly and to a greater extent than other IL-7-dependent populations such as T cells<sup>38</sup>. Blockade of IL-7 during *Citrobacter* infection compromises the intestinal barrier, and IL-7 induction during infection drives ILC3 expansion required for normal barrier function<sup>40</sup>. Loss of ILC3 in LNs following IL-7 ablation also reveals a hitherto unappreciated role for these cells in regulating lymphocyte migration<sup>38</sup>. Thus, ILC function in immune homeostasis appears highly susceptible to perturbations in IL-7 function.

### IL-7 and IL-7R in the context of chronic inflammation and autoimmunity

As highlighted above, lack of IL-7–IL-7R-mediated signaling compromises lymphoid development and homeostasis. Its role in supporting normal immunity is evident in mechanisms that promote antiviral immune responses and limit organ toxicity<sup>41</sup>. However, abnormally high or unregulated levels of IL-7 and IL-7R also associate with immunopathology. IL-7 is thought to support aberrant immune activity in autoimmune diseases such as diabetes and multiple sclerosis<sup>42</sup>, and in chronic inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis and inflammatory bowel disease<sup>43–46</sup>. Individuals with Crohn's disease and ulcerative colitis display high IL-7 and IL-7R levels, and evidence of colon-specific increased mucosal IL-7R signaling, with colonic IL-7R $\alpha$  expression predicting resistance to anti-TNF therapy<sup>44,47</sup>. Notably, antibody-mediated IL-7R blockade reduces human T cell homing to the gut and colitis in humanized mouse models<sup>47</sup>.



**Fig. 2 | Developmental functions of IL-7.** During hematopoiesis, IL-7 signaling is important in supporting development of multiple lymphoid lineages. IL-7 signaling promotes commitment of progenitors to B cell fate, but is also essential for development of group 2 and group 3 ILCs in BM. In the thymus, IL-7 signaling promotes  $\gamma\delta$  T cell lineage development but is also essential to support expansion of DN4  $\alpha\beta$  thymocytes as they proliferate and fill the thymus with DP thymocytes ready for selection.

## IL-7 and IL-7R in hematological cancers


**IL-7 in T cell acute lymphoblastic leukemia (T-ALL).** Can IL-7R-mediated signaling promote proliferation to such an extent that it contributes to the development of lymphoid tumors? In vitro evidence that IL-7, including that produced by BM and thymic stromal cells, can induce survival and proliferation of T-ALL cells is extensive (reviewed in ref. <sup>48</sup>). In fact, more than 70% of individuals with T-ALL present with IL-7R-positive blasts<sup>49</sup>, and the response correlates with IL-7R $\alpha$  expression in leukemia cells<sup>49,50</sup>. In contrast to normal thymocytes, IL-7 appears to stimulate T-ALL cells irrespective of their maturation block, including at the DP stage<sup>51</sup>, although frequency of response may be higher in more immature cases<sup>50</sup>. Correlative data from AKR/J mice, whose thymocytes naturally overexpress IL-7R $\alpha$  and tend to develop thymic T cell lymphomas<sup>52</sup>, and from individuals with T-ALL, whose blasts present with evidence of IL-7 consumption<sup>53</sup>, suggest that IL-7-mediated signaling contributes to leukemia development in vivo. Findings from IL-7 transgenic mice<sup>54,55</sup> and xenotransplant of human T-ALL cells into IL-7-deficient mice<sup>53</sup> support this possibility.

Several mechanisms increase IL-7R $\alpha$  expression in T-ALL. For example, *NOTCH1*, a major T cell oncogene, activates *IL7R* transcription, which in turn is involved in Notch-mediated T-ALL cell maintenance<sup>56</sup>. Furthermore, elevated levels of the transcription factor ZEB2—including as a result of the chromosomal translocation t(2;14)(q22;q32)—lead to *IL7R* transcriptional upregulation<sup>57</sup>. Ribosomal protein L10 (RPL10) R98S substitution upregulates IL-7R $\alpha$  and downstream signaling elements<sup>58</sup>; mutations in Dynamin 2 (DNM2)<sup>59</sup>, which regulates IL-7R $\alpha$  trafficking and surface availability, may potentiate IL-7R-mediated signaling; and SOCS5 epigenetic silencing upregulates IL-7R $\alpha$  and JAK-STAT signaling<sup>60</sup>.

**IL-7 in B-ALL.** IL-7 also induces proliferation in vitro of B-ALL cells<sup>61</sup> and promotes B cell tumorigenesis in IL-7 transgenic mice<sup>54</sup>, whereas high levels of *IL7R* expression have been associated with CNS involvement and relapse in pediatric B-ALL<sup>62</sup>. In addition, IL-7R $\alpha$  is fundamental for B-ALL arising in mice from combined STAT5 activation and PAX5 transcription factor haploinsufficiency<sup>63</sup>, and B-ALL development in the context of infection

exposure and PAX5 deficiency involves a pre-leukemic state that is hypersensitive to IL-7, subsequently originating leukemia via acquisition of JAK3 and JAK1 substitutions<sup>64</sup>. B cell linker (BLNK, also known as SLP-65) inactivation occurs in human B-ALL, and mouse BLNK-deficient leukemia cells display constitutive JAK3-STAT5 signaling triggered by autocrine IL-7<sup>65</sup>. Accordingly, BLNK deficiency cooperates with constitutive activation of STAT5, a major IL-7 signaling effector, in promoting mouse B cell leukemogenesis<sup>65</sup>. Ikaros (encoded by *IKZF1*) is a critical tumor suppressor, often inactivated in B-ALL, whose role in pre-B cell differentiation relies largely on turning off IL-7-dependent gene expression<sup>66</sup>, likely by directly repressing *IL7R* and competing with STAT5 DNA binding<sup>67</sup>. SH2B adaptor protein 3 (SH2B3, also known as LNK) binds JAK3 and regulates pro-B cell homeostasis by decreasing IL-7-triggered JAK-STAT5 signaling. Accordingly, pre-leukemic B cell progenitors with combined loss of *SH2B3* and the tumor suppressor gene *TP53* (p53) are hyper-responsive to IL-7 on their path to B-ALL<sup>68</sup>.

**IL-7-mediated signaling in healthy and leukemic cells.** We will now focus on T-ALL to consider why IL-7 may preferentially benefit leukemia cells at the expense of their normal counterparts (Fig. 3). For one, IL-7 promotes the expansion of T-ALL cells but does not overcome their differentiation block<sup>69</sup>. This means that IL-7 positive effects on developmentally arrested malignant precursors can be ‘perpetuated’ in the absence of ensuing differentiation checkpoints. By contrast, normal thymocytes benefit from IL-7 transiently, but inevitably differentiate and undergo stringent processes of selection that are at the core of T cell development, against which T-ALL cells are largely protected by their maturation arrest. Additionally, the activation of oncogenes that strongly promote proliferation, such as that encoding c-MYC, can often trigger apoptosis—an effect that can be counterbalanced by external cues. MYC is frequently activated in T-ALL<sup>70</sup>, although its ability to drive malignant transformation per se is debated<sup>71</sup>. Pre-leukemic cells with aberrant MYC activation will thus benefit from an IL-7-rich environment that protects them against oncogene-induced apoptosis, offering time for the acquisition of additional mutations. Oncogenic insults suffered by (pre)malignant cells may also shape how they respond to microenvironmental cues. As noted above, different oncogenic



**Fig. 3 | Potential mechanisms promoting outgrowth of leukemia cells in the context of IL-7 stimulation, which could explain how a limited resource such as IL-7 may benefit more (pre)leukemic cells than normal lymphoid precursors.** **a**, Maturation arrest is a characteristic of both B-ALL and T-ALL cells that protects them from stringent selection steps that necessarily occur as a lymphoid precursor differentiates in the bone marrow or thymus, while fully benefiting from the survival and proliferative signals arising from IL-7 signaling. **b**, Oncogenic hits such as MYC activation often lead to cancer development only if complemented by secondary hits that counterbalance oncogene-induced apoptosis. IL-7 provides non-cell-autonomous prosurvival cues that should allow (pre)leukemic cells to thrive, buying time for subsequent fully transforming lesions to occur and subsequent (more aggressive) leukemia development. **c**, Different genetic lesions such as intracellular Notch (ICN1), ZEB2 translocation (tZEB2) or mutations in ribosomal genes (RPLmut) in T-ALL, or SH2B3 or PAX5 deficiency in B-ALL, lead to IL-7R $\alpha$  upregulation and consequent IL-7 hypersensitivity. **d**, (Pre)leukemic cells can downregulate the production of IL-7 by stromal cells in such a way that normal precursors fail to fully access an essential factor for their development, while full transformation or hyperresponsiveness to IL-7 may allow for expansion of the malignant cells in low IL-7-containing niches.

insults upregulate IL-7R $\alpha$  in T-ALL and pre-leukemic B cells often are IL-7-hypersensitive. This is especially relevant given that (pre)leukemic cells may actively instruct stromal cells to downregulate IL-7 production in specific niches, decreasing IL-7 availability for normal precursors<sup>72</sup>.

IL-7 binding promotes IL-7R $\alpha$  and  $\gamma$ c heterodimerization, leading to JAK1 and JAK3 activation and consequent downstream signaling, most notably STAT1, STAT3 and STAT5 as well as PI3K-Akt-mTOR and MEK-ERK pathways. However, T-ALL cells appear to differ from normal T cells in the recruitment of signaling pathways toward particular cellular responses to IL-7 (reviewed in ref.<sup>31</sup>). PI3K signaling is involved in IL-7-induced cell cycle progression<sup>73</sup> without impacting cell survival or Bcl-2 expression<sup>74</sup> in naive T cells. In contrast, PI3K-Akt-mTOR signaling is essential for IL-7-mediated proliferation and survival of T-ALL cells by promoting both downregulation of the cell cycle checkpoint kinase p27<sup>kip1</sup> as well as Bcl-2 upregulation<sup>75,76</sup>. In agreement, IL-7-mediated Bcl-2 upregulation in T-ALL cells appears to be STAT5-independent<sup>77</sup>, again in opposition to the fact that IL-7-mediated STAT5 activation in naive T cells associates with survival<sup>73</sup>, suggesting that IL-7-mediated Bcl-2 upregulation occurs via STAT5 in normal T cells. Overall, although normal and leukemic T cells recruit the same signaling axes downstream from IL-7-IL-7R, they may exploit them to achieve different functional outcomes. These differences have potential therapeutic relevance, as PI3K-Akt-mTOR pathway inhibitors should preferentially eliminate IL-7-dependent T-ALL cells while being merely cytostatic for peripheral T cells.

**IL7R gain-of-function mutations.** *IL7R* gene amplification was reported in T-ALL<sup>78</sup>, although the consequences for leukemogenesis are unknown. In contrast, *IL7R* mutational activation is a driver of ALL<sup>79–84</sup>. Somatic gain-of-function mutations in IL-7R $\alpha$  lead to

constitutive activation of the receptor promoting cell transformation in vitro and tumor formation in vivo. They were identified in around 10% of T-ALL cases and more rarely in B-ALL<sup>79,80</sup>, where they were enriched in particular subgroups, especially in cases that are Philadelphia-like (Ph-like), or that display TSLP receptor (TSLPR-CRLF2) gene rearrangements (CRLF2-rearranged), intrachromosomal amplification of chromosome 21 (iAMP21) or particular mutations in the tumor suppressor genes encoding IKAROS family zinc finger 1 (IKZF1 N159Y) or paired box 5 (PAX5 P80R)<sup>80,85</sup>. Although enriched in individuals overexpressing homeobox A (*HOXA*) and T cell leukemia homeobox (*TLX*) genes<sup>79</sup> and frequent in early T cell precursor ALL (ETP-ALL)<sup>81</sup>, *IL7R* mutations occur in all T-ALL subtypes<sup>84</sup>.

Mutations in *IL7R* are somatic, heterozygous and affect either exon 5 or 6, falling into four classes (Fig. 4). Type 1a mutations are the most frequent, occur in exon 6, and are insertions or insertions-deletions that include an unpaired cysteine in the extracellular juxtamembrane-transmembrane (EJMT) portion of IL-7R $\alpha$ , leading to disulfide-bond-dependent mutant receptor homodimerization and constitutive, ligand-independent signaling<sup>79</sup>. Type 1b mutations also affect exon 6 but insert non-cysteine residues within the transmembrane region closer to the cytosolic domain, including tryptophans, SxxxG-related motifs, or other residues that are suspected or formally have been shown to lead to ligand-independent IL-7R $\alpha$  dimerization<sup>79,86</sup>. Type 1c mutations impact the EJMT region, similar to type 1a but they result in insertion of positively charged amino acids that promote  $\gamma$ c heterodimerization and IL-7 hyperresponsiveness<sup>87</sup>. In contrast to the others, type 2 mutations are exclusive to B-ALL, affect exon 5 and lead to S185C substitution in the extracellular domain. They confer cytokine independence, but require TSLPR-CRLF2 and can increase responsiveness to the cytokine TSLP<sup>80</sup>.

The ability of mutant IL-7R per se to originate T-ALL or B-ALL in vivo when expressed in hematopoietic progenitors is yet to be demonstrated. Nonetheless, retroviral expression of mutant IL-7R $\alpha$  in hematopoietic stem and progenitor cells accelerated Notch-induced T-ALL, whereas in CLPs mutant IL-7R $\alpha$  alone caused mature B cell leukemia/lymphoma—but not B-ALL<sup>83</sup>. In a different study, mutant *IL7R* overexpression in DN thymocytes with inactivation of the *Ink4/Arf* tumor suppressor locus, from *Arf*<sup>-/-</sup> mice, induced thymocyte development arrest at an immature stage, eventually leading to ETP-ALL-like disease<sup>82</sup>. Likewise, mutant *IL7R* cooperated with *NRAS* G13D in inducing T-ALL from transplanted DN thymocytes<sup>88</sup>. Mutant *IL7R* alone caused multi-systemic inflammatory disease rather than leukemia<sup>88</sup>.

**IL-7R-mediated signals in resistance to therapy.** IL-7–IL-7R-mediated signaling may be critical for resistance to conventional chemotherapy and to targeted therapeutics. In T-ALL cells, exogenous IL-7 stimulation or mutational activation of IL-7R signaling elements (including the receptor itself) induce glucocorticoid resistance, which can be bypassed using the JAK inhibitor ruxolitinib or MEK, AKT, mTOR, or dual PI3K/mTOR inhibitors<sup>50,78,89,90</sup>. Notably, *IL7R* mutation associates with very poor prognosis in relapsed pediatric T-ALL cases<sup>91</sup>. Additionally, IL-7 promotes resistance to imatinib in Philadelphia-positive B-ALL cells in vitro<sup>92</sup> and likely contributes to the same phenomenon in vivo<sup>93</sup>. IL-7 may also mediate resistance to the mTOR inhibitor rapamycin<sup>94</sup>, which might be of relevance also for T-ALL<sup>75</sup>.

**IL-7 signaling in other hematological tumors.** An oncogenic role of the IL-7–IL-7R signaling axis may extend to other lymphoid tumors. For example, locally produced IL-7 promotes proliferation, residence and expression of c-Myb and Bcl-2 in cutaneous T cell lymphoma (CTCL) cells<sup>36</sup>. In agreement, IL-7 appears to be a growth factor for Sézary lymphoma cells, the leukemic form of CTCL<sup>95</sup>. Other hematological tumors where there is some evidence for IL-7–IL-7R axis involvement include chronic lymphocytic leukemia (CLL), T cell prolymphocytic leukemia (T-PLL), Hodgkin's lymphoma and even acute myeloid leukemia<sup>61,96</sup>. Stimulation of CLL and T-PLL cells with IL-7 induced their proliferation in vitro<sup>61</sup>. In contrast to mature B cells, CLL cells were reported to express IL-7R<sup>61</sup>. Moreover, there is evidence for some CLL cells producing IL-7<sup>97</sup>, which raises the possibility of an IL-7 autocrine loop existing in some patients.

**Potential tumor suppressor functions of IL-7 signaling.** Whereas excessive IL-7–IL-7R signaling is oncogenic, it is possible that, in particular spatial and developmental scenarios, diminished IL-7R-mediated signaling compromises homeostasis to a degree that paradoxically potentiates malignancy. In support of this notion, IL-7R $\alpha$  deficiency potentiates lymphomagenesis in *p53*-null mice by exacerbating telomere erosion in T cell precursors<sup>98</sup>. In such a scenario, *IL7R* appears to act more along the lines of a tumor suppressor than an oncogene. Likewise, IL-7R signaling prevents premature activation of activation-induced cytidine deaminase (AID) during B cell development<sup>99</sup>, protecting the B cell genome and potentially preventing leukemogenesis. The alternative is that by preventing AID activity and excessive genomic instability, while potentiating viability and proliferation, the IL-7–IL-7R axis actually creates the perfect milieu for transformation.

### IL-7 and IL-7R in solid tumors

IL-7 stimulates multiple immune-mediated mechanisms that contribute to the eradication of tumors. We will, however, continue to explore the pathological role of IL-7–IL-7R-mediated signaling, which can extend beyond hematological cancers (Fig. 5). Epithelial cancers can aberrantly express IL-7R $\alpha$  and IL-7, and may thus


benefit from their activity<sup>100–103</sup>. Evidently, effects on the immune system—including promoting inflammation—that indirectly contribute to generation of a pro-tumoral milieu are likely to occur<sup>104,105</sup>. Involvement of IL-7 and IL-7R in colon chronic inflammation agrees with the observation that individuals with metastatic colorectal cancer display high IL-7 levels<sup>14</sup> and that the cancer tissue itself can secrete IL-7<sup>106</sup>. Notably, high IL-7 and IL-7R expression in tumor tissues of individuals with breast and lung cancer correlates positively with LN metastasis and poorer survival<sup>100,101,107,108</sup>. Likewise, high IL-7 expression in prostate cancer<sup>109</sup> associates with poor prognosis<sup>110</sup>. These data are incompatible with increased T cell antitumoral activity and rather suggest IL-7–IL-7R pathophysiologically relevant activation loops in solid tumors. In agreement, *IL7R* gains were reported in lung<sup>111</sup>, pancreatic<sup>112</sup> and esophageal<sup>113</sup> carcinomas. Notably, network analysis of recurrently mutated genes revealed IL-7-mediated signaling activation during clonal evolution of breast cancer<sup>114</sup>.

Can IL-7 directly stimulate non-hematopoietic cancer cells? In vitro studies using cell lines suggest so. IL-7 promoted proliferation<sup>107</sup>, epithelial-mesenchymal transition and metastasis<sup>102</sup> of human breast cancer cells. Likewise, IL-7 stimulated prostate and bladder cancer cell migration, invasiveness and epithelial-mesenchymal transition<sup>110,115</sup>. In lung cancer, IL-7 stimulated the proliferation of tumor cells via cyclin D1 upregulation and appeared to promote tumor growth also in a subcutaneous xenotransplant mouse model<sup>116</sup>. The expression of IL-7R and cyclin D1 in the tumor tissue of individuals with lung cancer correlated positively, and the latter associated with poor prognosis<sup>116</sup>. In a mouse orthotopic breast cancer model, IL-7-expressing cancer-associated fibroblasts promoted tumor growth and maintenance of cancer stem-like cells<sup>103</sup>. IL-7 may also be critical in brain tumors, possibly contributing to resistance to cisplatin treatment in glioma<sup>117</sup>. IL-7 contribution to tumor development may further involve promotion of lymphangiogenesis<sup>108</sup> and osteoclastogenesis<sup>118</sup>.

### IL-7 traction for therapeutic purposes

**IL-7 administration in individuals with cancer.** Animal experiments have consistently shown that IL-7 administered pharmacologically could induce T cell expansion with little toxicity, suggesting IL-7 could have a therapeutic benefit in humans. Over 400 patients have now been treated with IL-7, with few toxicities other than a transient injection site reaction when administered subcutaneously (s.c.). In the earliest trials using non-glycosylated IL-7, IL-7 antibodies were elicited, but this response has apparently been alleviated using glycosylated IL-7 produced by Revimmune (formerly Cytheris Corp).

Cancer patients were the first humans to be treated with IL-7 (Table 1). Although there were no apparent anticancer benefits of IL-7, dramatic immunological effects were reported. The first trial included twelve individuals with metastatic melanoma and sarcoma<sup>119</sup>. Administration s.c. showed a serum half-life of about 12 hours. Injected eight times, three days apart, the highest IL-7 dose elicited a three- to sevenfold increase in circulating naive T cells, no increase in regulatory T cell (T<sub>reg</sub> cells) and, in some patients, an increase in B cell progenitors in the BM. A subsequent trial in 16 subjects with refractory cancer<sup>120</sup> confirmed the increase in naive T cells (but not T<sub>reg</sub> cells), showed this was likely due to increased cycling and Bcl-2-associated resistance to apoptosis, and demonstrated increased TCR diversity. Decreased T<sub>reg</sub> cell frequency was an important distinction from treatments with IL-2, a related  $\gamma$ c cytokine, which had the opposite effect. A study in individuals with lymphopenic breast cancer showed that IL-7 treatment before (but not during) chemotherapy increased CD4 counts<sup>121</sup>. A trial in children with sarcoma combined a tumor vaccine with IL-7, confirming IL-7 induced an increase in T cells and decreased T<sub>reg</sub> cells frequency, but without anti-cancer benefit<sup>122</sup>. A trial combining IL-7 with the vaccine Provenge in prostate cancer (CITN-03) showed a doubling



**Fig. 4 | Classes of *IL7R* gain-of-function mutants in leukemia.** **a**, *IL7Rα* mutants found in individuals with leukemia fall into four classes, affecting either exon 6 (type 1) or, less frequently, exon 5 (type 2). The latter are all S185C variants affecting the transmembrane domain and occur exclusively in individuals with B-ALL. Mutations affecting exon 6 are: type 1a, which are insertions or insertions-deletions introducing an unpaired cysteine in the extracellular juxtamembrane-transmembrane (EJMT) region; type 1b, which lie deeper in the transmembrane domain region and include tryptophans, SxxxG-related motifs, or other residues; and type 1c, which occur in the EJMT region but lead to the introduction of negatively charged amino acids such as arginine or histidine. UTR, untranslated region. **b**, Specificities on receptor dimerization and signaling resulting from each class of mutations.


of prostate-specific antigen (PSA)-reactive T cells that could predict a benefit in a sufficiently powered study. IL-7-Fc (NeoImmune Tech/Genexine) was reported to be well tolerated and to increase T cells in healthy subjects<sup>123</sup>. It is in phase 1b/2a trials combined with temozolomide in glioblastoma, and with the checkpoint inhibitor atezolizumab (anti-PD-L1) in skin cancers, melanoma, Merkel cell carcinoma and cutaneous squamous cell cancer. IL-7-Fc is also in a trial with pembrolizumab (anti-PD-1) in triple-negative breast cancer. Finally, IL-7-Fc will be combined with chimeric antigen receptor T cell therapy (CAR-T) in a trial in acute lymphoblastic leukemia, and a trial will combine Revimmune IL-7 with atezolizumab in urothelial cancer (NCT03513952).

In hematopoietic stem cell transplant patients, recovery of host T cells after ablation was increased twofold by IL-7 in a trial of 12 individuals treated for three weeks. Increases were largely in memory T cells with augmented TCR diversity and in vitro CMV responses<sup>120</sup>. A trial of IL-7 in cord blood transplantation (RevImmune/MD Anderson NCT03600896) is underway.

**IL-7 administration in HIV infection and other infectious diseases.** HIV infection was the first infectious disease to be investigated with IL-7 therapy. In 13 HIV-infected individuals who were concurrently treated with anti-retrovirals but had relatively low

CD4 T cell counts, IL-7 increased CD4 and CD8 T cell counts<sup>124</sup>. Increases, mainly in naive and central memory T cells, were up to sevenfold and counts remained elevated up to 45 weeks after discontinuation of IL-7. In 25 HIV-infected individuals treated with anti-retrovirals, increased central memory T cells were seen 14 days after a single injection s.c. of IL-7<sup>125,126</sup>. Concerns that IL-7 could promote HIV replication were not confirmed, as only a transient increase in viral transcripts was observed in a fraction of patients. Mucosa-associated invariant T cells are deficient in individuals with HIV infection despite anti-retroviral treatment. Increases of these cells by four- to fivefold were reported 12 weeks following three s.c. IL-7 injections<sup>126</sup>. IL-7 also elevated T cell counts in idiopathic (non-HIV) CD4-deficient patients<sup>127</sup>. There are discussions about testing IL-7 in individuals positive for HIV with mycobacterial infection and in individuals with multidrug resistant bacterial infections.

Progressive multifocal leukoencephalopathy (PML) is a severe, rare central nervous system infection caused by human polyomavirus 2 (also known as JC virus) in immunodeficient individuals. A single patient with idiopathic CD4 deficiency and PML, after an initial treatment with antivirals, was treated with IL-7, and showed a doubling of blood CD4 T cells and disappearance of viral sequences in cerebrospinal fluid<sup>128</sup>. Subsequent case reports of compassionate use of IL-7 in PML reported CD4 increases and patient improvement<sup>129</sup>.



**Fig. 5 | Potential pro-tumoral functions of IL-7R-mediated signaling in solid cancers.** In vitro and in vivo studies suggest that the IL-7-IL-7R axis is implicated in promoting proliferation, epithelial-mesenchymal transition (EMT), migration, invasion and metastasis, as well as resistance to chemotherapy of cancer cells, while also stimulating osteoclastogenesis in bone metastasis and lymphangiogenesis. In agreement, *IL7R* is amplified in different cancers and high levels of IL-7 and/or IL-7R can be associated with poor prognosis.

**Table 1 | IL-7 and IL-7R agonists and antagonists in human subjects**

Product	Source	Disease	Current/future trials
IL-7	Revimmune (Cytheris)	Cancers	CITN-03, NCT03513952
		HSCT	NCT03600896
		HIV	
		CD4 deficiency	
		Myco, MDR	Future
		PML	
IL-7-Fc	Neolmmune Tech	Cancers	Current and future
		Elderly	Plus vaccine, future
αIL-7R	Pfizer	T1D, MS	Current
	GSK	Sjogren's syndrome	Current
	OSE	IBD, Sjogren's syndrome	Future
	NCI/Fannin	ALL	Future

HSCT, hematopoietic stem cell transplantation; Myco, mycobacterial infection in individuals with AIDS; MDR, multi-drug resistant bacterial infections; T1D, type 1 diabetes; MS, multiple sclerosis; IBD, inflammatory bowel disease.

Sepsis is frequently fatal despite treatment with antibiotics. Recent studies have shown that much of this morbidity results not from the initiating pathogen but from loss of CD4 T cells and a subsequent rise in secondary infections<sup>130</sup>. IL-7 ex vivo was shown to greatly increase IFN-γ production by T cells from individuals with

sepsis<sup>131</sup>. A Phase 1 trial of IL-7 in individuals with sepsis showed significant improvement in CD4 counts, although subject numbers were too few to determine whether there was a clinical benefit<sup>132</sup>. A larger trial of IL-7 given intravenously (i.v.) in individuals with sepsis is planned (NCT03821038). At the US National Cancer Institute (NCI), IL-7-Fc will be combined with pathogen vaccines in aging individuals with cancer to determine whether expansion of T cell repertoire has functional effects.

**IL-7R pathway antagonists in the clinic**

As mentioned above, IL-7-IL-7R signaling has been implicated in autoimmune and chronic inflammatory diseases, as well as in cancer. Therapeutic targeting of the pathway could occur at several levels<sup>133</sup> and a number of clinical trials are underway and planned.

**Anti-IL-7R monoclonal antibodies (Mabs).** Blocking IL-7R with Mabs could blunt effector T cells but spare T<sub>reg</sub> cells in autoimmune disease. An antagonist anti-IL-7Rα MAb (Pfizer), tested in cynomolgus monkeys, blocked IL-7 in T cells ex vivo<sup>134</sup> and is in Phase I trials in individuals with type 1 diabetes and multiple sclerosis. Another antagonist anti-IL-7Rα MAb (GSK), in trial in multiple sclerosis, was halted prematurely for undisclosed reasons. However, a Phase IIa study in primary Sjogren's syndrome is underway. An antagonist anti-IL-7Rα MAb (OSE Immunotherapeutics) was tested in baboons, showed inhibition of a recall delayed type hypersensitivity response without T cell depletion<sup>135</sup>, and blocked human T cell homing to the gut in humanized mice<sup>47</sup>. A Phase I clinical trial is planned in healthy volunteers, aiming for Phase II evaluation in individuals with inflammatory bowel disease and Sjogren's syndrome. Cytotoxic anti-IL-7Rα Mabs, shown to be effective in translational studies in T cell acute lymphoblastic leukemia<sup>136</sup>, have been developed at NCI<sup>137</sup> and will be evaluated in clinical trials by Fannin LLC.

**Pharmacological signaling inhibitors.** The IL-7R pathway offers new druggable targets in ALL<sup>133</sup> that are beginning to be explored clinically. As mentioned above, ruxolitinib showed therapeutic benefit in translational studies of T-ALL<sup>79,138</sup>, especially in ETP-ALL cases<sup>50,89</sup>. St. Jude Children's Research Hospital will incorporate ruxolitinib into front-line therapy for ETP-ALL (NCT03117751). The PI3K and MEK pathways were also implicated in IL-7R-driven T-ALL<sup>76,90,139</sup>. Moreover, mutations in *IL7R* frequently occur together with Ras pathway mutations in ALL<sup>140</sup> and cooperate with the IL-7R pathway to drive T-ALL<sup>88</sup>. An upcoming trial in relapsed T-ALL will combine glucocorticoids with the MEK inhibitor selumetinib (ISRCTN92323261), a design based on synergy of these drugs against mutant Ras-driven T-ALL reported in preclinical studies<sup>141</sup>. Venetoclax is another small molecule that would target the IL-7R pathway by inhibiting Bcl-2<sup>49,75</sup>. Venetoclax was effective in preclinical studies in IL-7R-driven T-ALL<sup>138</sup> and is in clinical trial in ALL (NCT03236857, NCT03181126). Everolimus is an mTOR kinase inhibitor that is in trials in T-ALL (NCT03328104, NCT03740334). Other potential approaches to target IL-7R signaling in ALL have been recently reviewed<sup>133</sup>. Overall, a considerable fraction of individuals with T-ALL (and B-ALL) should benefit from treatment with inhibitors of IL-7R signaling.

Received: 7 June 2019; Accepted: 26 July 2019;  
Published online: 19 November 2019

## References

- Kim, G. Y., Hong, C. & Park, J.-H. Seeing is believing: illuminating the source of in vivo interleukin-7. *Immune Netw.* **11**, 1–10 (2011).
- Sawa, Y. et al. Hepatic interleukin-7 expression regulates T cell responses. *Immunity* **30**, 447–457 (2009).
- Moore, N. C., Anderson, G., Smith, C. A., Owen, J. J. & Jenkinson, E. J. Analysis of cytokine gene expression in subpopulations of freshly isolated thymocytes and thymic stromal cells using semiquantitative polymerase chain reaction. *Eur. J. Immunol.* **23**, 922–927 (1993).
- Link, A. et al. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. *Nat. Immunol.* **8**, 1255–1265 (2007).
- Onder, L. et al. IL-7-producing stromal cells are critical for lymph node remodeling. *Blood* **120**, 4675–4683 (2012).
- Iolyeva, M. et al. Interleukin-7 is produced by afferent lymphatic vessels and supports lymphatic drainage. *Blood* **122**, 2271–2281 (2013).
- Shinoda, K. et al. Thy1+IL-7+ lymphatic endothelial cells in iBALT provide a survival niche for memory T-helper cells in allergic airway inflammation. *Proc. Natl Acad. Sci. USA* **113**, E2842–E2851 (2016).
- Moors, M. et al. Interleukin-7 (IL-7) and IL-7 splice variants affect differentiation of human neural progenitor cells. *Genes Immun.* **11**, 11–20 (2010).
- Sinclair, C., Saini, M., Schim van der Loeff, I., Sakaguchi, S. & Seddon, B. The long-term survival potential of mature T lymphocytes is programmed during development in the thymus. *Sci. Signal.* **4**, ra77 (2011).
- Buentke, E. et al. Do CD8 effector cells need IL-7R expression to become resting memory cells? *Blood* **108**, 1949–1956 (2006).
- Leung, G.A. et al. The lymphoid-associated interleukin 7 receptor (IL7R) regulates tissue-resident macrophage development. *Development* <https://doi.org/10.1242/dev.176180> (2019).
- Nayar, S. et al. Bimodal expansion of the lymphatic vessels is regulated by the sequential expression of IL-7 and lymphotoxin  $\alpha 1\beta 2$  in newly formed tertiary lymphoid structures. *J. Immunol.* **197**, 1957–1967 (2016).
- Kondo, M., Weissman, I. L. & Akashi, K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. *Cell* **91**, 661–672 (1997).
- Dias, S., Silva, H. Jr., Cumano, A. & Vieira, P. Interleukin-7 is necessary to maintain the B cell potential in common lymphoid progenitors. *J. Exp. Med.* **201**, 971–979 (2005).
- Clark, M. R., Mandal, M., Ochiai, K. & Singh, H. Orchestrating B cell lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor signalling. *Nat. Rev. Immunol.* **14**, 69–80 (2014).
- Vosshenrich, C. A. J. et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. *Nat. Immunol.* **7**, 1217–1224 (2006).
- Shitara, S. et al. IL-7 produced by thymic epithelial cells plays a major role in the development of thymocytes and TCR $\gamma\delta^+$  intraepithelial lymphocytes. *J. Immunol.* **190**, 6173–6179 (2013).
- Boudil, A. et al. IL-7 coordinates proliferation, differentiation and Tcr $\alpha$  recombination during thymocyte  $\beta$ -selection. *Nat. Immunol.* **16**, 397–405 (2015).
- Hagenbeek, T. J. et al. The loss of PTEN allows TCR  $\alpha\beta$  lineage thymocytes to bypass IL-7 and pre-TCR-mediated signaling. *J. Exp. Med.* **200**, 883–894 (2004).
- Seddon, B. & Zamoyska, R. TCR and IL-7 receptor signals can operate independently or synergize to promote lymphopenia-induced expansion of naive T cells. *J. Immunol.* **169**, 3752–3759 (2002).
- Yu, Q. et al. Cytokine signal transduction is suppressed in preselection double-positive thymocytes and restored by positive selection. *J. Exp. Med.* **203**, 165–175 (2006).
- Kerdiles, Y. M. et al. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. *Nat. Immunol.* **10**, 176–184 (2009).
- Grenningloh, R. et al. Ets-1 maintains IL-7 receptor expression in peripheral T cells. *J. Immunol.* **186**, 969–976 (2011).
- Webb, L. V. et al. Survival of single positive thymocytes depends upon developmental control of RIPK1 kinase signaling by the IKK complex independent of NF- $\kappa$ B. *Immunity* **50**, 348–361.e4 (2019).
- Serafini, N., Vosshenrich, C. A. & Di Santo, J. P. Transcriptional regulation of innate lymphoid cell fate. *Nat. Rev. Immunol.* **15**, 415–428 (2015).
- Adachi, S. et al. Essential role of IL-7 receptor  $\alpha$  in the formation of Peyer's patch anlage. *Int. Immunol.* **10**, 1–6 (1998).
- Chappaz, S., Grtner, C., Rodewald, H.-R. & Finke, D. Kit ligand and Il7 differentially regulate Peyer's patch and lymph node development. *J. Immunol.* **185**, 3514–3519 (2010).
- Coles, M. C. et al. Role of T and NK cells and IL7/IL7r interactions during neonatal maturation of lymph nodes. *Proc. Natl Acad. Sci. USA* **103**, 13457–13462 (2006).
- Meier, D. et al. Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells. *Immunity* **26**, 643–654 (2007).
- Pearson, C., Silva, A. & Seddon, B. Exogenous amino acids are essential for interleukin-7 induced CD8 T cell growth. *PLoS One* **7**, e33998 (2012).
- Mazzucchelli, R. & Durum, S. K. Interleukin-7 receptor expression: intelligent design. *Nat. Rev. Immunol.* **7**, 144–154 (2007).
- Xue, H. H. et al. IL-2 negatively regulates IL-7 receptor  $\alpha$  chain expression in activated T lymphocytes. *Proc. Natl Acad. Sci. USA* **99**, 13759–13764 (2002).
- Kaech, S. M. et al. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. *Nat. Immunol.* **4**, 1191–1198 (2003).
- Seddon, B., Tomlinson, P. & Zamoyska, R. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. *Nat. Immunol.* **4**, 680–686 (2003).
- Schluns, K. S., Kieper, W. C., Jameson, S. C. & Lefrançois, L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. *Nat. Immunol.* **1**, 426–432 (2000).
- Adachi, T. et al. Hair follicle-derived IL-7 and IL-15 mediate skin-resident memory T cell homeostasis and lymphoma. *Nat. Med.* **21**, 1272–1279 (2015).
- Sumaria, N. et al. Cutaneous immunosurveillance by self-renewing dermal  $\gamma\delta$  T cells. *J. Exp. Med.* **208**, 505–518 (2011).
- Yang, J. et al. IL-7-dependent maintenance of ILC3s is required for normal entry of lymphocytes into lymph nodes. *J. Exp. Med.* **215**, 1069–1077 (2018).
- Martin, C. E. et al. Interleukin-7 availability is maintained by a hematopoietic cytokine sink comprising innate lymphoid cells and T cells. *Immunity* **47**, 171–182.e4 (2017).
- Zhang, W., Du, J.-Y., Yu, Q. & Jin, J.-O. Interleukin-7 produced by intestinal epithelial cells in response to Citrobacter rodentium infection plays a major role in innate immunity against this pathogen. *Infect. Immun.* **83**, 3213–3223 (2015).
- Pellegrini, M. et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. *Cell* **144**, 601–613 (2011).
- Lee, L. F. et al. Anti-IL-7 receptor- $\alpha$  reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. *Proc. Natl Acad. Sci. USA* **109**, 12674–12679 (2012).
- Churchman, S. M. & Ponchel, F. Interleukin-7 in rheumatoid arthritis. *Rheumatology (Oxford)* **47**, 753–759 (2008).
- Krzystek-Korpacka, M. et al. Elevated systemic interleukin-7 in patients with colorectal cancer and individuals at high risk of cancer: association with lymph node involvement and tumor location in the right colon. *Cancer Immunol. Immunother.* **66**, 171–179 (2017).
- Anderson, C. A. et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat. Genet.* **43**, 246–252 (2011).

46. Gracey, E. et al. IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. *Ann. Rheum. Dis.* **75**, 2124–2132 (2016).
47. Belarif, L. et al. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. *J. Clin. Invest.* **130**, 1910–1925 (2019).
48. Oliveira, M. L., Akkapeddi, P., Ribeiro, D., Melão, A. & Barata, J. T. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: an update. *Adv. Biol. Regul.* **71**, 88–96 (2019).
49. Karawajew, L. et al. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. *Blood* **96**, 297–306 (2000).
50. Maude, S. L. et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. *Blood* **125**, 1759–1767 (2015).
51. Barata, J. T. et al. Common gamma chain-signaling cytokines promote proliferation of T-cell acute lymphoblastic leukemia. *Haematologica* **89**, 1459–1467 (2004).
52. Laouar, Y., Crispe, I. N. & Flavell, R. A. Overexpression of IL-7 $\alpha$  provides a competitive advantage during early T-cell development. *Blood* **103**, 1985–1994 (2004).
53. Silva, A. et al. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. *Cancer Res.* **71**, 4780–4789 (2011).
54. Rich, B. E., Campos-Torres, J., Tepper, R. I., Moreadith, R. W. & Leder, P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. *J. Exp. Med.* **177**, 305–316 (1993).
55. Abraham, N. et al. Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas. *Oncogene* **24**, 5252–5257 (2005).
56. González-García, S. et al. CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7 $\alpha$  gene expression in early human thymopoiesis and leukemia. *J. Exp. Med.* **206**, 779–791 (2009).
57. Goossens, S. et al. ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. *Nat. Commun.* **6**, 5794 (2015).
58. Girardi, T. et al. The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling. *Leukemia* **32**, 809–819 (2018).
59. Tremblay, C. S. et al. Loss-of-function mutations of Dynamitin 2 promote T-ALL by enhancing IL-7 signalling. *Leukemia* **30**, 1993–2001 (2016).
60. Sharma, N. D. et al. Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia. *Cancer Sci.* **110**, 1931–1946 (2019).
61. Digel, W. et al. Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. *Blood* **78**, 753–759 (1991).
62. Alsadeq, A. et al. IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia. *Blood* **132**, 1614–1617 (2018).
63. Heltemes-Harris, L. M. et al. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. *J. Exp. Med.* **208**, 1135–1149 (2011).
64. Martín-Lorenzo, A. et al. Infection exposure is a causal factor in B-cell precursor acute lymphoblastic leukemia as a result of Pax5-inherited susceptibility. *Cancer Discov.* **5**, 1328–1343 (2015).
65. Nakayama, J. et al. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3. *Blood* **113**, 1483–1492 (2009).
66. Heizmann, B., Kastner, P. & Chan, S. Ikaros is absolutely required for pre-B cell differentiation by attenuating IL-7 signals. *J. Exp. Med.* **210**, 2823–2832 (2013).
67. Katerndahl, C. D. S. et al. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. *Nat. Immunol.* **18**, 694–704 (2017).
68. Cheng, Y. et al. LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors. *J. Clin. Invest.* **126**, 1267–1281 (2016).
69. Dibirdik, I. et al. Engagement of interleukin-7 receptor stimulates tyrosine phosphorylation, phosphoinositide turnover, and clonal proliferation of human T-lineage acute lymphoblastic leukemia cells. *Blood* **78**, 564–570 (1991).
70. Herranz, D. et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. *Nat. Med.* **20**, 1130–1137 (2014).
71. Loosveld, M. et al. MYC fails to efficiently shape malignant transformation in T-cell acute lymphoblastic leukemia. *Genes Chromosom. Cancer* **53**, 52–66 (2014).
72. Fistonich, C. et al. Cell circuits between B cell progenitors and IL-7<sup>+</sup> mesenchymal progenitor cells control B cell development. *J. Exp. Med.* **215**, 2586–2599 (2018).
73. Swanson, L. et al. IL-7-induced proliferation of recent thymic emigrants requires activation of the PI3K pathway. *Blood* **109**, 1034–1042 (2007).
74. Rathmell, J. C., Farkash, E. A., Gao, W. & Thompson, C. B. IL-7 enhances the survival and maintains the size of naive T cells. *J. Immunol.* **167**, 6869–6876 (2001).
75. Barata, J. T., Cardoso, A. A., Nadler, L. M. & Boussiotis, V. A. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27<sup>kip1</sup>. *Blood* **98**, 1524–1531 (2001).
76. Barata, J. T. et al. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. *J. Exp. Med.* **200**, 659–669 (2004).
77. Ribeiro, D. et al. STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells. *Blood Adv.* **2**, 2199–2213 (2018).
78. Li, Y. et al. IL-7 receptor mutations and steroid resistance in pediatric T cell acute lymphoblastic leukemia: a genome sequencing study. *PLoS Med.* **13**, e1002200 (2016).
79. Zenatti, P. P. et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. *Nat. Genet.* **43**, 932–939 (2011).
80. Shochat, C. et al. Gain-of-function mutations in interleukin-7 receptor- $\alpha$  (IL7R) in childhood acute lymphoblastic leukemias. *J. Exp. Med.* **208**, 901–908 (2011).
81. Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature* **481**, 157–163 (2012).
82. Treanor, L. M. et al. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. *J. Exp. Med.* **211**, 701–713 (2014).
83. Yokoyama, K. et al. In vivo leukemogenic potential of an interleukin 7 receptor  $\alpha$  chain mutant in hematopoietic stem and progenitor cells. *Blood* **122**, 4259–4263 (2013).
84. Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. *Nat. Genet.* **49**, 1211–1218 (2017).
85. Gu, Z. et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. *Nat. Genet.* **51**, 296–307 (2019).
86. Shochat, C. et al. Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. *Blood* **124**, 106–110 (2014).
87. Weijenborg Campos, L. et al. Oncogenic basic amino acid insertions at the extracellular juxtamembrane region of IL7RA cause receptor hypersensitivity. *Blood* **133**, 1259–1263 (2019).
88. Cramer, S. D. et al. Mutant IL-7R $\alpha$  and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia. *Leukemia* **32**, 1795–1882 (2018).
89. Delgado-Martin, C. et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. *Leukemia* **31**, 2568–2576 (2017).
90. Canté-Barrett, K. et al. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. *Leukemia* **30**, 1832–1843 (2016).
91. Richter-Pechańska, P. et al. Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia. *Blood Cancer J.* **7**, e523 (2017).
92. Williams, R. T., Roussel, M. F. & Sherr, C. J. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. *Proc. Natl Acad. Sci. USA* **103**, 6688–6693 (2006).
93. Williams, R. T., den Besten, W. & Sherr, C. J. Cytokine-dependent imatinib resistance in mouse BCR-ABL<sup>+</sup>, Arf-null lymphoblastic leukemia. *Genes Dev.* **21**, 2283–2287 (2007).
94. Brown, V. I. et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. *Proc. Natl Acad. Sci. USA* **100**, 15113–15118 (2003).
95. Dalloul, A. et al. Interleukin-7 is a growth factor for Sézary lymphoma cells. *J. Clin. Invest.* **90**, 1054–1060 (1992).
96. Cattaruzza, L. et al. Functional coexpression of interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. *Int. J. Cancer* **125**, 1092–1101 (2009).
97. Frishman, J., Long, B., Knospe, W., Gregory, S. & Plate, J. Genes for interleukin 7 are transcribed in leukemic cell subsets of individuals with chronic lymphocytic leukemia. *J. Exp. Med.* **177**, 955–964 (1993).
98. Kibe, R. et al. IL-7R $\alpha$  deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis. *Cell Death Differ.* **19**, 1139–1151 (2012).
99. Swaminathan, S. et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. *Nat. Immunol.* **16**, 766–774 (2015).
100. Al-Rawi, M. A., Rmali, K., Watkins, G., Mansel, R. E. & Jiang, W. G. Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. *Eur. J. Cancer* **40**, 494–502 (2004).

101. Suzuki, K. et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor  $\beta 2$  (IL-12R $\beta 2$ ), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. *J. Clin. Oncol.* **31**, 490–498 (2013).
102. Yang, J. et al. IL-7 splicing variant IL-7S5 induces EMT and metastasis of human breast cancer cell lines MCF-7 and BT-20 through activation of PI3K/Akt pathway. *Histochem. Cell Biol.* **142**, 401–410 (2014).
103. Boesch, M. et al. Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness. *Oncol Immunology* **7**, e1414129 (2018).
104. Li, J., Liu, J., Mao, X., Tang, Q. & Lu, H. IL-7 receptor blockade inhibits IL-17-producing  $\gamma\delta$  cells and suppresses melanoma development. *Inflammation* **37**, 1444–1452 (2014).
105. Chen, H. C. et al. IL-7-dependent compositional changes within the  $\gamma\delta$  T cell pool in lymph nodes during ageing lead to an unbalanced anti-tumour response. *EMBO Rep.* **20**, e47379 (2019).
106. Maeurer, M. J. et al. Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. *Scand. J. Immunol.* **45**, 182–192 (1997).
107. Al-Rawi, M. A., Rmali, K., Mansel, R. E. & Jiang, W. G. Interleukin 7 induces the growth of breast cancer cells through a wortmannin-sensitive pathway. *Br. J. Surg.* **91**, 61–68 (2004).
108. Ming, J., Zhang, Q., Qiu, X. & Wang, E. Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: a mechanism of lymphangiogenesis in lung cancer. *Eur. J. Cancer* **45**, 866–873 (2009).
109. Mengus, C. et al. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. *J. Transl. Med.* **9**, 162 (2011).
110. Qu, H. et al. IL-7/IL-7 receptor axis stimulates prostate cancer cell invasion and migration via AKT/NF- $\kappa$ B pathway. *Int. Immunopharmacol.* **40**, 203–210 (2016).
111. Sakre, N. et al. RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR. *Oncotarget* **8**, 5992–6002 (2017).
112. Liang, W. S. et al. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. *PLoS One* **7**, e43192 (2012).
113. Lin, D. C. et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. *Nat. Genet.* **46**, 467–473 (2014).
114. Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. *Nature* **486**, 395–399 (2012).
115. Seol, M. A. et al. Interleukin-7 contributes to the invasiveness of prostate cancer cells by promoting epithelial-mesenchymal transition. *Sci. Rep.* **9**, 6917 (2019).
116. Ming, J., Jiang, G., Zhang, Q., Qiu, X. & Wang, E. Interleukin-7 up-regulates cyclin D1 via activator protein-1 to promote proliferation of cell in lung cancer. *Cancer Immunol. Immunother.* **61**, 79–88 (2012).
117. Cui, L. et al. Overexpression of IL-7 enhances cisplatin resistance in glioma. *Cancer Biol. Ther.* **13**, 496–503 (2012).
118. Roato, I. et al. Bone invading NSCLC cells produce IL-7: mice model and human histologic data. *BMC Cancer* **10**, 12 (2010).
119. Rosenberg, S. A. et al. IL-7 administration to humans leads to expansion of CD8<sup>+</sup> and CD4<sup>+</sup> cells but a relative decrease of CD4<sup>+</sup> T-regulatory cells. *J. Immunother.* **29**, 313–319 (2006).
120. Sportès, C. et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. *J. Exp. Med.* **205**, 1701–1714 (2008).
121. Tredan, O. et al. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4<sup>+</sup> lymphocyte count in lymphopenic metastatic breast cancer patients. *Annals Onc.* **26**, 1353–1362 (2015).
122. Merchant, M. S. et al. Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas. *Clin. Cancer Res.* **22**, 3182–3191 (2016).
123. Kim, J.-H. et al. Abstract 4991: hyleukin-7, the Fc-fused interleukin-7, generates anti-tumor activity by modulating both adaptive and innate immune cells in the tumor microenvironment. *Cancer Res.* <https://doi.org/10.1158/1538-7445.AM2019-4991> (2019).
124. Levy, D. S., Kahana, J. A. & Kumar, R. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. *Blood* **113**, 1723–1729 (2009).
125. Sereti, I. et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. *Blood* **113**, 6304–6314 (2009).
126. Sortino, O. et al. IL-7 treatment supports CD8<sup>+</sup> mucosa-associated invariant T-cell restoration in HIV-1-infected patients on antiretroviral therapy. *AIDS* **32**, 825–828 (2018).
127. Sheikh, V. et al. Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia. *Blood* **127**, 977–988 (2016).
128. Patel, A., Patel, J. & Ikwuagwu, J. A case of progressive multifocal leukoencephalopathy and idiopathic CD4<sup>+</sup> lymphocytopenia. *J. Antimicrob. Chemother.* **65**, 2697–2698 (2010).
129. Alstadhaug, K. B. et al. Treatment of progressive multifocal leukoencephalopathy with interleukin 7. *JAMA Neurol.* **71**, 1030–1035 (2014).
130. Hotchkiss, R. S. et al. Sepsis and septic shock. *Nat. Rev. Dis. Primers* **2**, 16045 (2016).
131. Thampy, L. K. et al. Restoration of T Cell function in multi-drug resistant bacterial sepsis after interleukin-7, anti-PD-L1, and OX-40 administration. *PLoS One* **13**, e0199497 (2018).
132. Francois, B. et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. *JCI Insight* **3**, 98960 (2018).
133. Cramer, S. D., Aplan, P. D. & Durum, S. K. Therapeutic targeting of IL-7R $\alpha$  signaling pathways in ALL treatment. *Blood* **128**, 473–478 (2016).
134. Kern, B., Li, W., Bono, C., Lee, L. F. & Kraynov, E. Receptor occupancy and blocking of STAT5 signaling by an anti-IL-7 receptor  $\alpha$  antibody in cynomolgus monkeys. *Cytometry B Clin. Cytom.* **90**, 191–198 (2016).
135. Belarif, L. et al. IL-7 receptor blockade blunts antigen-specific memory T cell responses and chronic inflammation in primates. *Nat. Commun.* **9**, 4483 (2018).
136. Akkapeddi, P. et al. A fully human anti-IL-7R $\alpha$  antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia. *Leukemia* <https://doi.org/10.1038/s41375-019-0434-8> (2019).
137. Hixon, J. et al. New anti-IL-7R $\alpha$  monoclonal antibodies show efficacy against T-cell acute lymphoblastic leukemia in pre-clinical models. *Leukemia* <https://doi.org/10.1038/s41375-019-0531-8> (2019).
138. Senkevitch, E. et al. Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL-7R $\alpha$  mutations. *Oncotarget* **9**, 22605–22617 (2018).
139. Silva, A. et al. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells. *Leukemia* **25**, 960–967 (2011).
140. Roberts, K. G. et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. *Cancer Cell* **22**, 153–166 (2012).
141. Matheson, E.C. et al. Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM. *Haematologica* <https://doi.org/10.3324/haematol.2017.185975> (2019).

## Acknowledgements

We thank M. Morre (Revimmune), R. Hotchkiss (Washington University), M. Cheever (University of Washington), R. Gress (NCI), I. Sereti (NIAID), N. Poirier (OSE Immunotherapeutics), C. Foley and A. Veradhachary (Fannin LLC) and E. Schafer (Baylor University) for sharing information on clinical trials, and M. Fernandes for help with draft figure preparation. J.T.B. is funded by the consolidator grant ERC CoG-648455 from the European Research Council, under the European Union's Horizon 2020 research and innovation programme, and the FAPESP/20015/2014 and PTDC/MEC-HEM/31588/2017 grants from Fundação para a Ciência e a Tecnologia, Portugal; S.K.D. is funded by the intramural program of the US National Cancer Institute, National Institutes of Health, and the Children's Cancer Foundation; B.S. is funded by the MRC (United Kingdom) under U117573801 and MR/P011225/1.

## Author contributions

J.T.B., S.K.D. and B.S. wrote the manuscript and approved its final version.

## Competing interests

S.K.D. is a co-inventor on the patent application "IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia" filed by the NIH (DHHS). US Patent Application No. 62/238,612.

## Additional information

Correspondence should be addressed to J.T.B.

**Peer review information** Zoltan Fehervari was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Springer Nature America, Inc. 2019